BD (NYSE:BDX) announced today that it completed the acquisition of flow cytometry solution developer Cytognos. Salamanca, Spain-based Cytognos specializes in flow cytometry solutions for blood cancer diagnosis, minimal residual disease (MRD) detection, and immune monitoring research for blood diseases. Franklin Lakes, New Jersey–based BD said in a news release that the acquisition accelerates its strategy […]